Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis
NCT ID: NCT01321164
Last Updated: 2014-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
30 participants
INTERVENTIONAL
2011-04-30
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis
NCT00811005
Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.
NCT00407342
Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects
NCT00658606
Effect Narrow-Band UVB Radiations
NCT05647187
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
NCT00470392
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fumaric acid esters
Fumaric acid esters monotherapy
Fumaric acid esters
Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
fumaric acid esters plus narrow band UVB
Combination therapy of fumaric acid esters plus narrow band type B ultraviolet therapy (UVB)
Full Body UV Therapy System UV 7002 plus fumaric acid esters
Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.
Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Full Body UV Therapy System UV 7002 plus fumaric acid esters
Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.
Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months
Fumaric acid esters
Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 80 years old
Exclusion Criteria
* cancer, chronic infections, autoimmune diseases
* gastrointestinal illnesses
* liver diseases
* renal malfunctions
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adrian Tanew
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrian Tanew, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Medical University of Vienna, Department of Dermatology, Division of General Dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Vienna; Department of Dermatology
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FPUVB 005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.